Syncona

London, United Kingdom Founded: 2012 • Age: 14 yrs
Healthcare investments are managed via private equity by Syncona.
Annual revenue $125.6M Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products 2 Services tracked
Competitors - Brand Intelligence

About Syncona

Syncona is a company based in London (United Kingdom) founded in 2012. Syncona has completed 4 acquisitions, including Applied Genetics Technologies Corporation, Freeline and Omass. Syncona offers products and services including Investment Management and Portfolio Development.

  • Headquarter London, United Kingdom
  • Stage Public
  • Sectors
    Financial Services
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Syncona Ltd Gbp
Operational Areas
Financial Services → Private Capital & Alternative Investments Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $125.56 M (USD)
    65.61
    as on Mar 31, 2025
  • Net Profit
    -$185.34 M (USD)
    -3879.3
    as on Mar 31, 2025
  • EBITDA
    -$184.41 M (USD)
    -3508.38
    as on Mar 31, 2025
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    Not available
  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Syncona

Syncona is a publicly listed company on the LSE with ticker symbol SYNC in UK, operating in the Miscellaneous sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: LSE · Ticker: SYNC · Sector: Miscellaneous · UK

Products & Services of Syncona

Syncona offers a comprehensive portfolio of products and services, including Investment Management and Portfolio Development.

Product name locked
Category locked
Primary

Investments are managed in life science companies to support development of therapeutics

Product name locked
Category locked
Locked

Portfolios are developed by building and overseeing biotechnology firms across clinical stages

People of Syncona

Headcount 10-50
Employee Profiles 25
Board Members and Advisors 11
Employee Profiles
People
Magdalena Jonikas
Lead Partner
People
Chris Hollowood
CEO
People
Nikki Padden
Finance Director, Launch
People
Michael Kyriakides
Investment Partner

Unlock access to complete

Board Members and Advisors
people
Charles Swanton
Founder
people
Karl Peggs
Founder
people
Sergio Quezada
Founder
people
Mark Lowdell
Founder

Unlock access to complete

Funding Insights of Syncona

Premium access

Detailed funding history for Syncona

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Syncona

Syncona has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Applied Genetics Technologies Corporation, Freeline and Omass.

Investments
Premium access

Investment portfolio details for Syncona

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Native mass spectrometry services for protein characterization are provided.
Locked Locked 2016 Locked
Gene therapy platform is developed for chronic disease treatments.
Locked Locked 2015 Locked
Clinical-stage biotech company advancing gene therapies for rare and neurological diseases.
Locked Locked 2015 Locked
Premium access

Complete acquisition details for Syncona

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Syncona

Premium access

Detailed financials for Syncona

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Syncona Comparisons

Syncona Primary company
Description
Healthcare investments are managed via private equity by Syn...
Location
London, United Kingdom
Founded Year
2012
Annual Revenue
$125.56 M (USD)
Net Profit
-$185.34 M (USD)
EBITDA
-$184.41 M (USD)
Employees
Not available
Premium access

Peer comparison for Syncona

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Syncona

Premium access

Detailed competitors of Syncona

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Syncona

Premium access

Complete news archive for Syncona

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Syncona

Syncona was founded in 2012.

Syncona is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.

Annual revenue of Syncona is $125.56M as on Mar 31, 2025.

Syncona was founded in 2012 and is headquartered in London, United Kingdom. Focus is placed on private equity investments within the healthcare sector, where portfolio companies are supported through funding and strategic guidance. Operations encompass identifying and nurturing early-stage biotechs and medtech firms, with a team of partners and directors overseeing activities from the UK base. Services include capital deployment and operational expertise for healthcare innovators.

Syncona offers Investment Management and Portfolio Development.

Yes, Syncona is publicly traded on LSE under the ticker symbol SYNC.

Syncona has made 4 acquisitions, including Applied Genetics Technologies Corporation, Freeline, and Omass.

The ticker symbol of Syncona is SYNC on LSE.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available